Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Published Online
on December 27, 2005

Hypertension. 2005
Published online before print December 27, 2005, doi: 10.1161/01.HYP.0000196950.48596.21
A more recent version of this article appeared on March 1, 2006
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
47/3/537    most recent
01.HYP.0000196950.48596.21v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Padia, S. H.
Right arrow Articles by Carey, R. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Padia, S. H.
Right arrow Articles by Carey, R. M.
Related Collections
Right arrow ACE/Angiotension receptors

Submitted on September 20, 2005
Revised on October 21, 2005

Renal Angiotensin Type 2 Receptors Mediate Natriuresis Via Angiotensin III in the Angiotensin II Type 1 Receptor-Blocked Rat

Shetal H. Padia; Nancy L. Howell; Helmy M. Siragy; and Robert M. Carey*

From the Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Virginia Health System, Charlottesville.

* To whom correspondence should be addressed. E-mail: rmc4C{at}virginia.edu.

Abstract--Whereas angiotensin (Ang) II is the major effector peptide of the renin-angiotensin system, its metabolite, des-aspartyl1-Ang II (Ang III), may also have biologic activity. We investigated the effects of renal interstitial (RI) administration of candesartan (CAND), a specific Ang II type 1 receptor (AT1) blocker, with and without coinfusion of PD-123319 (PD), a specific Ang II type 2 receptor (AT2) blocker, on Na+ excretion (UNaV) in uninephrectomized rats. We also studied the effects of unilateral RI infusion of Ang II or Ang III on UNaV with and without systemic infusion of CAND with the noninfused kidney as control. In rats receiving normal Na+ intake, RI CAND increased UNaV from 0.07±0.08 to 0.82±0.17 µmol/min (P<0.01); this response was abolished by PD. During Na+ restriction, CAND increased UNaV from 0.06±0.02 to 0.1±0.02 µmol/min (P<0.05); this response also was blocked by PD. In rats with both kidneys intact, in the absence of CAND, unilateral RI infusion of Ang III did not significantly alter UNaV. However, with systemic CAND infusion, RI Ang III increased UNaV from 0.08±0.01 µmol/min to 0.18±0.04 µmol/min (P<0.01) at 3.5 nmol/kg per minute, and UNaV remained elevated throughout the infusion; this response was abolished by PD. However, RI infusion of Ang II did not significantly alter UNaV at any infusion rate (3.5 to 80 nmol/kg per minute) with or without systemic CAND infusion. These results suggest that intrarenal AT1 receptor blockade engenders natriuresis by activation of AT2 receptors. AT2 receptor activation via Ang III, but not via Ang II, mediates the natriuretic response in the presence of systemic AT1 receptor blockade.


Key words: angiotensin • sodium • natriuresis • angiotensin • receptors, angiotensin II




This article has been cited by other articles:


Home page
HypertensionHome page
S. H. Padia, B. A. Kemp, N. L. Howell, J. J. Gildea, S. R. Keller, and R. M. Carey
Intrarenal Angiotensin III Infusion Induces Natriuresis and Angiotensin Type 2 Receptor Translocation in Wistar-Kyoto but not in Spontaneously Hypertensive Rats
Hypertension, February 1, 2009; 53(2): 338 - 343.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
L. E. Yang, M. B. Sandberg, A. D. Can, K. Pihakaski-Maunsbach, and A. A. McDonough
Effects of dietary salt on renal Na+ transporter subcellular distribution, abundance, and phosphorylation status
Am J Physiol Renal Physiol, October 1, 2008; 295(4): F1003 - F1016.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
S. H. Padia, B. A. Kemp, N. L. Howell, M.-C. Fournie-Zaluski, B. P. Roques, and R. M. Carey
Conversion of Renal Angiotensin II to Angiotensin III Is Critical for AT2 Receptor-Mediated Natriuresis In Rats
Hypertension, February 1, 2008; 51(2): 460 - 465.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
S. H. Padia, B. A. Kemp, N. L. Howell, H. M. Siragy, M.-C. Fournie-Zaluski, B. P. Roques, and R. M. Carey
Intrarenal Aminopeptidase N Inhibition Augments Natriuretic Responses to Angiotensin III in Angiotensin Type 1 Receptor-Blocked Rats
Hypertension, March 1, 2007; 49(3): 625 - 630.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
L. J. Salomone, N. L. Howell, H. E. McGrath, B. A. Kemp, S. R. Keller, J. J. Gildea, R. A. Felder, and R. M. Carey
Intrarenal Dopamine D1-Like Receptor Stimulation Induces Natriuresis via an Angiotensin Type-2 Receptor Mechanism
Hypertension, January 1, 2007; 49(1): 155 - 161.
[Abstract] [Full Text] [PDF]